(Q50908802)

25 March 2018

title

PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. (English)

1 reference

25 March 2018

0 references

2

1 reference

25 March 2018

Annamaria Morelli

4

1 reference

25 March 2018

Mario Maggi

13

object named as

Mario Maggi

1 reference

25 March 2018

Linda Vignozzi

1

1 reference

25 March 2018

Ilaria Cellai

3

1 reference

25 March 2018

Elena Maneschi

5

1 reference

25 March 2018

Paolo Comeglio

6

1 reference

25 March 2018

Raffaella Santi

7

1 reference

25 March 2018

Sandra Filippi

8

1 reference

25 March 2018

Arcangelo Sebastianelli

9

1 reference

25 March 2018

Gabriella Nesi

10

1 reference

25 March 2018

Sergio Serni

11

1 reference

25 March 2018

Marco Carini

12

1 reference

25 March 2018

publication date

13 June 2013

1 reference

25 March 2018

published in

The Prostate

1 reference

25 March 2018

volume

73

1 reference

25 March 2018

issue

13

1 reference

25 March 2018

page(s)

1391-1402

1 reference

25 March 2018

Abdominal obesity and metabolic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

The correlation between metabolic syndrome and prostatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Metabolic factors associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Insulin-resistance and benign prostatic hyperplasia: the connection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Estrogen receptor alpha is essential for the proliferation of prostatic smooth muscle cells stimulated by 17β-estradiol and insulin-like growth factor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Characterization and functional role of androgen-dependent PDE5 activity in the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Testosterone/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Identification, characterization and biological activity of oxytocin receptor in the developing human penis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

The hypocholesterolemic activity of orally administered polyene macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Different effects of soluble and particulate guanylyl cyclases on expression of inflammatory cytokines in rat peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Overexpression of cGMP-dependent protein kinase I (PKG-I) attenuates ischemia-reperfusion-induced kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Knockdown of lung phosphodiesterase 2A attenuates alveolar inflammation and protein leak in a two-hit mouse model of acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Genetic ablation of cGMP-dependent protein kinase type I causes liver inflammation and fasting hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Neutrophil dysfunction in guanosine 3',5'-cyclic monophosphate-dependent protein kinase I-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22686

21 January 2018

Identifiers

DOI

10.1002/PROS.22686

1 reference

25 March 2018

1 reference

25 March 2018